Heading into December, it felt like enactment of a drug price negotiation program in the US Medicare program was all but inevitable.
As 2022 begins, however, that inevitability is very much in doubt, after Sen. Joe Manchin’s (D-W.Va.) declaration of opposition to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?